3:11 PM
 | 
Jun 01, 2018
 |  BioCentury  |  Emerging Company Profile

Scratching the surface

Oppilotech’s model finds new targets for Gram-negative antibiotic potentiators

Oppilotech Ltd. is using computational modeling to develop first-in-class compounds that can permeate the lipopolysaccharide layer of the outer cell membrane of Gram-negative bacteria to potentiate existing antibiotics.

Marketed polymyxins are used to disrupt the lipopolysaccharide (LPS) to treat Gram-negative infections, but they have neurotoxic and nephrotoxic side effects that limit use to last resort cases.

“What polymyxins do is more like a drill. It disrupts the outer membrane by drilling holes through the LPS,” said CEO Ajay Mistry. “We’re down-regulating a molecule that makes LPS as opposed to physically destructing the LPS.”

Oppilotech uses a computational model of the lipid A synthesis pathway to identify novel targets that down-regulate lipid A, a key component of the LPS. Mistry said the model, which Oppilotech exclusively licensed...

Read the full 614 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >